Abstract
Introduction: Imatinib mesylate is first line therapy for chronic phase chronic myeloid leukemia (CML). Serositis is a rare, life-threatening, imatinib-induced complication, reported in 1.3% of newly diagnosed and 2% of other chronic phase CML patients, that may result in respiratory compromise or cardiac tamponade.
Case Presentation: 72-year-old-male with CML in molecular remission on imatinib presented with recurrent pleural effusions and new pericardial effusions concerning for pre-tamponade physiology, suspected to be imatinib induced serositis. Imatinib was discontinued with resolution of effusions. The patient was transitioned to nilotinib with maintenance of BCR-ABL negativity and good tolerability.
Conclusion: This case highlights the importance of recognizing imatinib-induced serositis. Prompt therapy modification can prevent morbidity while maintaining molecular remission.
Recommended Citation
Pillai, Maya; Khalid, Fatima; Sarker, Pallab; and Zimmerman, Ryan
(2026)
"Imatinib-Induced Serositis: A Rare Cause of Recurrent Pleural and Pericardial Effusions,"
Journal of Community Hospital Internal Medicine Perspectives: Vol. 16:
Iss.
6, Article 14.
DOI: https://doi.org/10.55729/2000-9666.1659
Available at:
https://scholarlycommons.gbmc.org/jchimp/vol16/iss6/14
DOI
10.55729/2000-9666.1659
